Trial Profile
A retrospective study of cetuximab-containing regimens in patients with recurrent/metastatic squamous cell head and neck carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2018
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Paclitaxel (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress